Breaking the Dual Barriers of Stratum Corneum and Blood–Brain Barrier: Development of Optimized Zein nanoparticles for Risperidone Brain Delivery
Biomedical Materials & Devices · 16.11.2026
DOI: 10.1007/s44174-026-00771-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Materials & Devices, online erschienen am 16.11.2026. Verfasst von Marwa H. Abdo und 2 weiteren Autor:innen. Die Arbeit nennt 77 Literaturangaben.
Abstract (Originalsprache)
Risperidone has poor bioavailability and a first pass effect, making transdermal delivery a promising option. Development of RSP zein nanoparticles was able to enhance the transdermal permeability of RSP. The PAMPA blood-brain permeability study confirmed successful brain delivery of RSP zein nanoparticles. Risperidone (RSP) is an atypical antipsychotic whose therapeutic efficacy is limited by extensive first-pass metabolism causing poor oral bioavailability. This study aimed to optimize RSP-loaded zein nanoparticles (RSP-ZNPs) to enhance transdermal flux and blood–brain barrier (BBB) permeability. A Box–Behnken design was implemented to optimize formulation variables (zein, Poloxamer 407 concentrations, and stirring speed), for certain critical attributes; particle size and % entrapment efficiency (EE) as dependent responses. Optimum RSP-ZNPs formulation was characterized for particle size, zeta potential, morphology using transmission electron microscopy (TEM), and in-vitro release. Transdermal efficiency and BBB penetration were quantified using ex-vivo skin permeability and Parallel Artificial Membrane Permeability Assay for BBB (PAMPA-BBB), respectively. Optimized RSP-loaded zein nanoparticles exhibited a particle size of 230.50±3.03 nm, EE of 80.0±2.3%, and good stability (zeta potential of −25.4±0.44 mV). TEM confirmed monodisperse, spherical nanoparticles with smooth surfaces. In-vitro release of optimized RSP-ZNPs demonstrated a biphasic pattern, with initial burst release followed by sustained release. RSP-ZNPs achieved a 3.5-fold enhancement in ex-vivo transdermal flux compared to RSP suspension. Furthermore, PAMPA-BBB assay exhibited two-fold increase in brain permeability ( Pe =9.4×10⁻^5 cm/s) compared to RSP suspension. Overall, these findings demonstrate that the developed zein nanoplatform enhances skin permeability and BBB transport, offering a promising NPs for use in transdermal delivery. Graphical abstract
Zitieren
APA
Abdo, M. H., El-Fattah, M. A. A., & Darwish, M. K. (2026). Breaking the Dual Barriers of Stratum Corneum and Blood–Brain Barrier: Development of Optimized Zein nanoparticles for Risperidone Brain Delivery. Biomedical Materials & Devices. https://doi.org/10.1007/s44174-026-00771-5
Vancouver
Abdo MH, El-Fattah MAA, Darwish MK. Breaking the Dual Barriers of Stratum Corneum and Blood–Brain Barrier: Development of Optimized Zein nanoparticles for Risperidone Brain Delivery. Biomedical Materials & Devices. 2026. doi:10.1007/s44174-026-00771-5
BibTeX
@article{Abdo2026,
author = {Abdo, Marwa H. and El-Fattah, Marwa A. Abd and Darwish, Manal K.},
title = {Breaking the Dual Barriers of Stratum Corneum and Blood–Brain Barrier: Development of Optimized Zein nanoparticles for Risperidone Brain Delivery},
journal = {Biomedical Materials & Devices},
year = {2026},
doi = {10.1007/s44174-026-00771-5}
}
EUVIMED